Stockscreener 앱 받기
51.29
0.73%
0.37
시간 외 거래:
51.29
Veracyte Inc 주식(VCYT)의 최신 뉴스
Veracyte (VCYT) director Jens Holstein awarded 5,272 restricted stock units - Stock Titan
Veracyte (VCYT) director Eliav Barr receives 5,272 restricted stock units - Stock Titan
Director at Veracyte (VCYT) receives grant of 5,272 restricted stock units - Stock Titan
Evan Jones of Veracyte (NASDAQ: VCYT) receives 5,272 restricted stock units - Stock Titan
Veracyte (VCYT) director Robert Epstein receives 5,272-share RSU grant - Stock Titan
Veracyte (VCYT) director awarded 5,272 RSUs vesting over one year - Stock Titan
Veracyte, Inc. 2023 Equity Incentive Plan Amended – SEC 8-K Filing Details and Company Information - Minichart
FMR LLC's Strategic Acquisition of Veracyte Inc Shares - GuruFocus
Veracyte (VCYT) investors back 3.5M-share equity plan increase and elect full board - Stock Titan
Veracyte (NASDAQ:VCYT) Hits New 12-Month HighHere's Why - MarketBeat
Why Veracyte (VCYT) is a top momentum stock for the long term - MSN
Here's why Veracyte (VCYT) is a strong growth stock - MSN
Veracyte Inc Annual Shareholders Meeting Transcript - GuruFocus
Here's how much a $1000 investment in Veracyte made 10 years ago would be worth today - MSN
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Veracyte, Inc. $VCYT Shares Sold by Amova Asset Management Americas Inc. - MarketBeat
Veracyte, Inc. $VCYT Shares Sold by GW&K Investment Management LLC - MarketBeat
Veracyte Inc (VCYT) Stock Down 3.0% but Still Overvalued -- GF S - GuruFocus
Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Why is Veracyte (VCYT) up 18.2% since last earnings report? - MSN
Veracyte (VCYT) Is Up 9.4% After New Phase III Data Validates Prosigna Chemotherapy-Guidance Role – Has The Bull Case Changed? - Sahm
FMR LLC holds 8.06M Veracyte (VCYT) shares, representing 10.1% - Stock Titan
Veracyte Insider Sold Shares Worth $6,919,585, According to a Recent SEC Filing - marketscreener.com
Veracyte EVP Annie McGuire sells $158k in company stock By Investing.com - Investing.com UK
Veracyte CFO Rebecca Chambers sells $177,082 in company stock By Investing.com - Investing.com Canada
Veracyte global chief commercial off sells $699,732 in stock By Investing.com - Investing.com South Africa
Veracyte CEO Marc Stapley sells $6.9m in company shares By Investing.com - Investing.com South Africa
Veracyte CFO Rebecca Chambers sells $177,082 in company stock - Investing.com
Veracyte (VCYT) CFO trades shares as RSUs vest and 10b5-1 plan executes - Stock Titan
Veracyte (VCYT) CAO reports 1,361 shares withheld for RSU tax obligations - Stock Titan
Veracyte global chief commercial off sells $699,732 in stock - Investing.com
Veracyte CEO Marc Stapley sells $6.9m in company shares - Investing.com
[144] VERACYTE, INC. SEC Filing - stocktitan.net
VCYT (NASDAQ) insider 10b5-1 sale of 10,204 shares; 3,176 RSUs registered - Stock Titan
VCYT Stock Price, Quote & Chart | VERACYTE INC (NASDAQ:VCYT) - ChartMill
How Veracyte (VCYT) Investors Can Read The Latest Unchanged Analyst Call - Yahoo Finance
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report? - Yahoo Finance
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate CancerSlideshow (NASDAQ:VCYT) 2026-06-03 - Seeking Alpha
Veracyte, Inc. (VCYT) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
Veracyte stock price target maintained at $42 by Canaccord on study results - Investing.com South Africa
Veracyte (VCYT) Launches Prosigna Breast Cancer Risk Test in the U.S. - GuruFocus
Wolfe Research initiates Veracyte stock coverage with Outperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates Veracyte stock coverage with Outperform rating - Investing.com
1.63%
2.88%
자본화:
|
볼륨(24시간):